11 completed, 7 terminated, 4 unknown, 1 active not recruiting. 24 Phase 2, 5 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 11, Terminated 7, Unknown 4, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 5 | Completed 4, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Acute Heart Failure: new trials by email Literature Review of Acute Heart Failure trials Research Report on Acute Heart Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure Dapagliflozin 10mg, Acetazolamide 500mg - Acute Heart Failure | Phase 2 / Phase 3 | Completed | Mansoura University | 108 | 2024-08-15 | 2026-10-26 |
| Oxygen Targets in Acute Heart Failure With Pulmonary Congestion Oxygen - Acute Heart Failure, Pulmonary Congestion | Phase 2 / Phase 3 | Completed | Copenhagen University Hospital, Hvidovre | 135 | 2024-02-01 | 2026-10-26 |
| Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure. Furosemide Injection - Acute Heart Failure | Phase 1 / Phase 2 | Completed | Johannes Grand | 20 | 2023-09-01 | 2024-02-16 |
| Efficacy and Safety of corticoSTEROids Added to Standard Therapy in Patients With Acute Heart Failure (STERO-AHF) Dexamethasone, Prednisone - Acute Heart Failure | Phase 2 / Phase 3 | Unknown | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 120 | 2023-04-24 | 2023-12-04 |
| Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers ( CORTAHF ) Prednisone arm, Usual care - Acute Heart Failure | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 3 | 2023-02-16 | 2026-01-21 |
| Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE) Protocolized diuretic therapy - Heart Failure, Acute Heart Failure | Phase 2 | Active not recruiting | Vanderbilt University Medical Center | 474 | 2022-05-01 | 2026-09-21 |
| Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF) Dapagliflozin 10mg Tab, Placebo - Acute Heart Failure | Phase 2 / Phase 3 | Completed | Mansoura University | 87 | 2022-04-25 | 2023-08-04 |
| Early Administration of Ivabradine in Children With Heart Failure Ivabradine 5Mg Tab - Acute Heart Failure, Dilated Cardiomyopathy | Phase 2 | Unknown | Bambino Gesù Hospital and Research Institute | 9 | 2020-06-20 | 2020-12-08 |
| Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE) Adrecizumab - Acute Heart Failure | Phase 2 | Unknown | GREAT Network Italy | 30 | 2019-12-15 | 2021-03-09 |
| EMPA Acute Heart Failure Empagliflozin, Placebo - Diabetes Mellitus, Type 2, Acute Heart Failure | Phase 2 | Terminated | RWTH Aachen University | 19 | 2018-06-11 | 2022-10-27 |
| Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study subcutaneous furosemide and sc2wear device - Acute Heart Failure, Decompensated Heart Failure | Phase 2 | Terminated | Adrian Hernandez | 11 | 2018-04-27 | 2019-01-23 |
| Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study Spironolactone, Placebo - Acute Heart Failure | Phase 2 | Withdrawn | Indiana University | 2015-05-01 | 2017-04-21 | |
| Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure Serelaxin - Acute Heart Failure | Phase 2 | Terminated | Novartis Pharmaceuticals | 12 | 2014-09-05 | 2019-06-25 |
| A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure CXL-1427, Placebo - Heart Failure, Decompensated Heart Failure | Phase 2 | Completed | Bristol-Myers Squibb | 70 | 2014-06-30 | 2019-07-31 |
| Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients Serelaxin, Placebo - Acute Heart Failure | Phase 2 | Completed | Novartis Pharmaceuticals | 46 | 2014-01-01 | 2015-10-12 |
| Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) Liraglutide, Placebo - Acute Heart Failure | Phase 2 | Completed | Duke University | 300 | 2013-04-01 | 2017-02-15 |
| Recombinant BNP on Heart and Renal Function in Acute Heart Failure rhBNP, standard of care - Acute Heart Failure, Acute Renal Failure | Phase 2 | Unknown | Shanghai Chest Hospital | 100 | 2012-07-01 | 2012-08-07 |
| Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure RLX030, Placebo - Acute Heart Failure | Phase 2 | Completed | Novartis Pharmaceuticals | 71 | 2012-03-01 | 2014-08-05 |
| Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children Levosimendan, Conventional intensified inotropic treatment - Acute Heart Failure | Phase 2 | Terminated | Jose Luis Vazquez Martinez | 116 | 2011-02-01 | 2013-01-31 |
| Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study Placebo, Nesiritide, Dopamine - Acute Heart Failure | Phase 2 | Completed | Duke University | 360 | 2010-08-01 | 2014-08-21 |
Showing 20 of 24. Sign in to see all of them.
Heart Failure (6) · Emergencies (3) · Acute Kidney Injury (1) · Cardiomyopathies (1) · Cardiomyopathy, Dilated (1) · Cardiovascular Diseases (1) · Diabetes Mellitus, Type 2 (1) · Hemophilia A (1) · Hypoxia (1) · Inflammation (1) · Pulmonary Edema (1) · Renal Insufficiency (1)
Heart Diseases (6) · Cardiovascular Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Disease Attributes (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genetic Diseases, Inborn (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Blood Coagulation Disorders (1) · Blood Coagulation Disorders, Inherited (1)
serelaxin protein, human (3) · BAY 58-2667 (2) · dapagliflozin (2) · Acetazolamide (1) · Dexamethasone (1) · Dopamine (1) · Exercise (1) · Furosemide (1) · Glucose (1) · Ivabradine (1) · Liraglutide (1) · Natriuretic Peptide, Brain (1) · Oxygen (1) · Potassium Acetate (1) · Prednisone (1)
Novartis Pharmaceuticals (3) · Bayer (2) · Duke University (2) · Mansoura University (2) · Adrian Hernandez (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Bambino Gesù Hospital and Research Institute (1) · Bristol-Myers Squibb (1) · Copenhagen University Hospital, Hvidovre (1) · GREAT Network Italy (1) · Indiana University (1) · Johannes Grand (1) · Jose Luis Vazquez Martinez (1) · Nepean Blue Mountains Local Health District (1)
United States (8) · Germany (6) · Italy (4) · Denmark (3) · Poland (3) · Russia (3) · Argentina (2) · Austria (2) · Egypt (2) · France (2) · Japan (2) · Switzerland (2) · Australia (1) · Belgium (1) · Canada (1)
Adrian Hernandez, MD (2) · Eugene Braunwald, MD (2) · Moheb Magdy Mouris, MD (2) · Noha Mansour, PhD (2) · Eugene Bruanwald, MD (1) · Fang Yuan (1) · Ida Taraldsen, MD (1) · Jens Hove, MD, PhD (1) · Johannes Grand (1) · Johannes Grand, MD, PhD (1) · Jose Luis Vazquez MArtinez, MD (1) · Kerry L Lee, PhD (1) · Mads Halbirk, dr. (1)
PMID 22713287, PMID 24046475, PMID 24247300, PMID 24255129, PMID 24666826, PMID 26927285, PMID 27483064, PMID 27512103, PMID 27514750, PMID 30120812, PMID 32362166, PMID 32473378, PMID 35654972, PMID 37544492, PMID 37923161, PMID 38447632, PMID 38903022, PMID 41773006
2009 (3), 2017 (1), 2019 (1), U01HL084904 (1), U10HL084904 (1)